Riggs Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,300
| Closed | -$39.3K | – | 762 |
|
|
2025
Q2 | $39.3K | Hold |
2,300
| – | – | 0.01% | 186 |
|
|
2025
Q1 | $147K | Hold |
2,300
| – | – | 0.04% | 114 |
|
|
2024
Q4 | $279K | Hold |
2,300
| – | – | 0.07% | 84 |
|
|
2024
Q3 | $287K | Buy |
2,300
+2,000
| +667% | +$276K | 0.08% | 87 |
|
|
2024
Q2 | $47.4K | Buy |
300
+75
| +33% | +$9.63K | 0.01% | 142 |
|
|
2024
Q1 | $29.1K | Buy |
225
+125
| +125% | +$15.3K | 0.01% | 165 |
|
|
2023
Q4 | $9.64K | Buy |
+100
| New | +$9.59K | ﹤0.01% | 248 |
|
|
2021
Q4 | – | Sell |
-35
| Closed | -$3K | – | 336 |
|
|
2021
Q3 | $3K | Hold |
35
| – | – | ﹤0.01% | 292 |
|
|
2021
Q2 | $3K | Hold |
35
| – | – | ﹤0.01% | 289 |
|
|
2021
Q1 | $3K | Hold |
35
| – | – | ﹤0.01% | 259 |
|
|
2020
Q4 | $6K | Sell |
35
-279
| -89% | -$41.3K | ﹤0.01% | 219 |
|
|
2020
Q3 | $97K | Buy |
314
+279
| +797% | +$42.4K | 0.04% | 83 |
|
|
2020
Q2 | $5K | Hold |
35
| – | – | ﹤0.01% | 205 |
|
|
2020
Q1 | $3K | Hold |
35
| – | – | ﹤0.01% | 220 |
|
|
2019
Q4 | $5K | Hold |
35
| – | – | ﹤0.01% | 238 |
|
|
2019
Q3 | $2K | Hold |
35
| – | – | ﹤0.01% | 224 |
|
|
2019
Q2 | $5K | Hold |
35
| – | – | ﹤0.01% | 210 |
|
|
2019
Q1 | $4K | Hold |
35
| – | – | ﹤0.01% | 207 |
|
|
2018
Q4 | $4K | Hold |
35
| – | – | ﹤0.01% | 192 |
|
|
2018
Q3 | $5K | Hold |
35
| – | – | ﹤0.01% | 193 |
|
|
2018
Q2 | $5K | Hold |
35
| – | – | ﹤0.01% | 208 |
|
|
2018
Q1 | $3K | Hold |
35
| – | – | ﹤0.01% | 253 |
|
|
2017
Q4 | $2K | Hold |
35
| – | – | ﹤0.01% | 255 |
|
|
2017
Q3 | $2K | Hold |
35
| – | – | ﹤0.01% | 251 |
|
|
2017
Q2 | $1K | Hold |
35
| – | – | ﹤0.01% | 284 |
|
|
2017
Q1 | $1K | Hold |
35
| – | – | ﹤0.01% | 264 |
|
|
2016
Q4 | $1K | Hold |
35
| – | – | ﹤0.01% | 254 |
|
|
2016
Q3 | $2K | Sell |
35
-40
| -53% | -$1.21K | ﹤0.01% | 248 |
|
|
2016
Q2 | $1K | Hold |
75
| – | – | ﹤0.01% | 252 |
|
|
2016
Q1 | $1K | Hold |
75
| – | – | ﹤0.01% | 246 |
|
|
2015
Q4 | $3K | Hold |
75
| – | – | ﹤0.01% | 236 |
|
|
2015
Q3 | $2K | Hold |
75
| – | – | ﹤0.01% | 237 |
|
|
2015
Q2 | $2K | Hold |
75
| – | – | ﹤0.01% | 286 |
|
|
2015
Q1 | $1K | Hold |
75
| – | – | ﹤0.01% | 286 |
|
|
2014
Q4 | $1K | Hold |
75
| – | – | ﹤0.01% | 282 |
|
|
2014
Q3 | $2K | Buy |
+75
| New | +$1.69K | ﹤0.01% | 272 |
|
Other funds holding SRPT
EAM
Riggs Asset Management's SRPT Position: Q3 2025 in Review
Riggs Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 2,300 shares — an estimated $39.3K sold.
Riggs Asset Management first reported a position in SRPT in Q3 2014 and held it in 36 quarters. The position peaked at $287K in Q3 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Riggs Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
- Riggs Asset Management sold 2,300 Sarepta Therapeutics shares in Q3 2025, an estimated $39.3K.
- Riggs Asset Management first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 36 quarters.
- Riggs Asset Management's Sarepta Therapeutics position peaked at $287K in Q3 2024.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.